SP
Sun Pharma Advanced Research Company Ltd (SPARC)
₹216.23
Mkt cap
₹7,017 Cr
P/E ratio
4.49
P/B
5.26
Div yield
0.00%
ROE
281.00%
ROCE
165.00%
EPS (TTM)
₹48.16
Book value
₹41
52W range
109–278
Sector
Healthcare
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products. [1]
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−22.10% from high₹216
₹109+98.91% from low₹278
Current
₹216.23
Prev close
₹217.00
Day
−0.35%
Price performance
1D
−0.35%
1W
−4.96%
1M
−3.86%
3M
+55.25%
6M
+68.94%
1Y
+33.95%
YTD
+59.32%
Financials
FRevenue, profit & margin
P/E ratio
4.5×
SPARC is 87% below the sector median of 34.0×
SPARC4.5×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 48 | 24 | 21 | 14 | 17 | 17 | 13 | 15 | 27 | 10 | 8 | 8 | 1,853 | |
| Expenses | 137 | 126 | 113 | 116 | 124 | 112 | 117 | 89 | 81 | 62 | 74 | 65 | 80 | |
| Operating Profit | -90 | -102 | -91 | -103 | -108 | -95 | -104 | -74 | -54 | -52 | -66 | -57 | 1,773 | |
| OPM % | -188% | -427% | -432% | -740% | -649% | -566% | -808% | -499% | -198% | -543% | -838% | -673% | 96% | |
| Other Income | 11 | 10 | 8 | 6 | 4 | 2 | 0 | 0 | 0 | 9 | 0 | -12 | 2 | |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 5 | 6 | 8 | 9 | 12 | |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | |
| Profit before tax | -82 | -95 | -86 | -100 | -107 | -97 | -108 | -80 | -61 | -52 | -76 | -81 | 1,761 | |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
| Net Profit | -82 | -95 | -86 | -100 | -107 | -97 | -108 | -80 | -61 | -52 | -76 | -81 | 1,761 | |
| EPS in Rs | -2.53 | -2.94 | -2.66 | -3.07 | -3.29 | -2.98 | -3.32 | -2.46 | -1.88 | -1.60 | -2.34 | -2.48 | 54.26 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Jun 202665.68%Promoter
Promoters65.68%0.01
FIIs3.90%1.86
DIIs0.09%0.79
Public30.34%1.07
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| SPARC | ₹216.23 | 4.49 | 7,017 | 0.00% | 1,761 | +2,987.34% | 1,853 | +6,715.81% | 164.99% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2026bseFinancial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012bse
Concall transcripts23
TranscriptJan 2026PPTJan 2026TranscriptDec 2024PPTDec 2024TranscriptApr 2024RECApr 2024TranscriptJan 2024TranscriptJan 2024PPTJan 2024PPTJan 2024TranscriptNov 2023PPTNov 2023TranscriptOct 2022PPTOct 2022TranscriptDec 2021PPTDec 2021PPTDec 2021PPTDec 2021PPTSep 2020PPTSep 2019PPTSep 2018PPTSep 2018PPTAug 2016
Credit ratings5
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 17 Jul - Newspaper Advertisement of 21st Annual General Meeting of Company and related informationBusiness Responsibility and Sustainability Reporting (BRSR) 16 Jul - SPARC submitted FY2025-26 BRSR with the annual report ahead of the 21st AGM.Notice Of 21St Annual General Meeting To Be Held On August 10, 2026 Along With The Annual Report For FY 26 16 JulReg. 34 (1) Annual Report. 16 JulAnnouncement under Regulation 30 (LODR)-Change in Directorate 13 Jul - Anil Raghavan to become Managing Director and CEO from Aug 11, 2026; Dr. Rajamannar Thennati retires Aug 10, 2026.